← All trials
NCT01802385
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2015
- Primary completion
- Sep 1, 2017
- Completion date
- Sep 27, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MinnesotaLead sponsor
- University of MinnesotaStudy director
- University of MinnesotaStudy chair
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Mbarara University of Science and TechnologyCollaborator
- Medical Research CouncilCollaborator
- Makerere UniversityCollaborator
- Infectious Disease Institute, Kampala, UgandaCollaborator
- Wellcome TrustCollaborator
- Infectious Disease Institute, Kampala, UgandaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.